News | July 19, 2007

Bioresorbable Collagen Scaffold Treats PFO

July 20, 2007 – Oraganogenesis Inc. announced that it has received regulatory approval in Canada and Europe for BioSTAR, a device that incorporates a bioresorbable collagen scaffold used to treat patent foramen ovale (PFO), a hole in the heart that is usually asymptomatic.
BioSTAR contains FortaFlex, an innovative bioresorbable collagen scaffold that consists of highly purified and very strong sheets of collagen. FortaFlex is a modular platform technology that can be custom bioengineered to meet the needs of a variety of surgical applications using a unique lamination and crosslinking process. The BioSTAR device incorporates the FortaFlex bioresorbable collagen scaffold to function like a pair of small umbrellas. When the BioSTAR device is deployed at the PFO, an umbrella of FortaFlex sits on both the right and left atrium of the heart, effectively closing the hole between the heart chambers. Reportedly, 90-95 percent of the implant is absorbed over time and replaced with the patient’s own tissue. Micro-emboli and unfiltered blood are therefore blocked from passing into the arterial circulation and thus averting a potential stroke.

For more information: www.organogenesis.com

Related Content

Videos | Structural Heart Occluders| November 08, 2017
John Rhodes, M.D., co-director of the adult congenital heart program, Medical University of South Carolina, is the pr
Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
University of Alabama at Birmingham, Amplatzer PFO Occluder, first implementation
News | Structural Heart Occluders| February 15, 2017
Doctors at the University of Alabama at Birmingham have implemented the first U.S. Food and Drug Administration (FDA)-...
Amplatzer PFO Occluder, St. Jude Medical, Baylor Heart and Vascular Services, Fort Worth, Texas, first patients
News | Structural Heart Occluders| February 01, 2017
Baylor Heart and Vascular Services at Fort Worth in November became the first program in Texas to implant the Amplatzer...
RESPECT trial, Amplatzer PFO Occluder, St. Jude Medical, TCT 2016
News | Structural Heart Occluders| November 02, 2016
St. Jude Medical Inc. announced the long-term data from RESPECT, a landmark trial, during a First Report session at the...
St. Jude Medical, Amplatzer PFO Occluder, FDA approval, U.S. launch
Technology | Structural Heart Occluders| November 02, 2016
St. Jude Medical Inc. announced this week the U.S. Food and Drug Administration (FDA) approval and launch of the...
PFO closure, patent foramen ovale, AAN recommendation, American Academy of Neurology, stroke patients
News | Structural Heart Occluders| August 08, 2016
Updated recommendations from the American Academy of Neurology (AAN) states that catheter-based closure should not be...
Videos | Structural Heart Occluders| June 16, 2016
This is an animation, supplied by Gore, demonstrated how the Cardioform Septal Occluder is implanted for the transcat
PFO occluder, amplatzer
Feature | Structural Heart Occluders| May 27, 2016 | Dave Fornell
May 27, 2016 — A U.S.
Videos | Structural Heart Occluders| November 05, 2012
Positive results from the RESPECT trial of transcatheter PFO vs.
Overlay Init